Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a relatively new class of anti-diabetic medications that have exhibited very promising results in the treatment of type 2 diabetes mellitus (T2DM) [1]. This evidence concerns the gene GLP1R and diabetes mellitus.